HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 04, April 2018 – Digestive health in the 21st century - Trust your guts       » Food wasted in China could feed 30-50 million       » Chinese scientists analyze human brain's "CPU"       » $150,000 fundraiser launched to sequence South Asian genomes       » Green tea-based drug carriers improve cancer treatment       » Scientists grow liver cancer cells in lab      
BIOBOARD - SWEDEN
Study shows DuPont probiotics impact intestinal microbiota in colon cancer patients
Breakthrough results show probiotic intervention can positively alter and modify intestinal microbiota in patients with colon cancer.

A recent research study conducted by the Sahlgrenska Academy at University of Gothenburg in Gothenburg, Sweden, in collaboration with DuPont Nutrition & Health (DuPont), yielded breakthrough results demonstrating that probiotic intervention can alter and modify intestinal microbiota in patients with colon cancer.

The study was based on the principle that the human gut microbiota contributes to metabolism, interacts with the immune system and protects against pathogens, so it has the potential to substantially impact overall health and well-being.

What defines a healthy microbiome can differ widely for individuals, but recent studies have shown that the gut microbiome is often dysbiotic, or altered from its normal stable state, in diseases such as gastrointestinal disorders, cancer, obesity and metabolic syndrome.

Recent advances in the sequencing technologies used to characterize the microbiome have led to an extensive investment in research focused on the discovery of new therapeutic strategies based on manipulation of the microbiome.

The key finding in the DuPont-backed research study was that the composition and diversity of the microbiota was altered in the tumor tissue and surrounding mucosa in biopsy samples taken from colon cancer patients when compared to non-cancer patients. This colon-cancer associated microbiota was modified by probiotic intervention and characterized by an increase of bacteria known to produce butyrate. The anti-inflammatory benefits of butyrate for colon health are well-documented, and it also has been shown to suppress the growth of colon cancer cells.

“Colorectal cancer (CRC) is one of the top three cancers diagnosed globally each year, and the risk of colorectal cancer is strongly correlated to lifestyle factors such as diet,” said Ashley Hibberd, staff associate investigator, DuPont Nutrition & Health. “The results of our study show that the risk component from diet may be mediated by the microbiota, and that the specific probiotic strains used in this study have the potential to support the microbiota in a beneficial way.”

DuPont probiotic strains Bifidobacterium animalis subsp. lactis Bl-04 and Lactobacillus acidophilus NCFM were manufactured into a protective matrix tablet innovation (ProBion) developed by Wasa Medicals, Sweden.

“The CRC-associated microbiota is being continuously defined as new biomarkers of CRC are discovered,” said Yvonne Wettergren, Ph.D., the Sahlgrenska Academy at University of Gothenburg. “The microbial dysbiosis observed in patients with CRC may be manipulated by probiotic bacteria if protected by the ProBion matrix, and the probiotic strains used in this study promise as a beneficial component of enhancing the microbiome in CRC.”

Source: DuPont

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy